ZVRAZevra Therapeutics, Inc.
Is it safe?
Mostly sound, with a caveat: comfortable debt (AA), but big price swings.
Net cash and profitable. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -98% · now 25% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can ZVRA take a bad year?
Zevra Therapeutics, Inc. holds $222M more cash than debt, so a bad year is a question about profits, not about lenders.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Interest cover
- 14.4×
Interest cover · operating profit covers the interest bill several times over
- Annualised volatility
- 58%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Total debtQ2 2026
- $0
- Cash and short-term investments
- $222M
- Net cash
- $222M
- EBITDA, trailing twelve months
- $84M
- Operating profit, trailing twelve months
- $82M
- Debt / equity
- 0.00×
- Total debt / EBITDA
- 0.00×
- Annualised volatilitytwo years of daily moves
- 58%
- Worst drawdown on file
- −98%
- Below its 52-week high
- 25%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.